Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stellar Zogenix Phase III Epilepsy Data Lift ZX008's Competitive Position

Executive Summary

Company is planning to file in the second half with two pivotal studies, but says it is "worth exploring" with the US FDA whether data from the first study could support an application.

You may also be interested in...



Zogenix' ZX008 Emerges As Strong Contender In Rare Epilepsy

Strong efficacy and a clean safety profile – with no cardiovascular signal – in another Phase III study bode well for filings of Zogenix's ZX008 in the fourth quarter.

GW's Epidiolex Approval Encouraging For Pharma-grade Cannabinoid Pipeline

Beyond Epidiolex for severe epilepsy, cannabinoid candidates are in development for a range of diseases, including acute pain, graft-versus-host disease, scleroderma, schizophrenia, pain and substance use disorder.

Keeping Track: DMD, RMAT, HIV, BTDs, Tc-99m – FTW

The latest drug development news and highlights from our US FDA Performance Tracker.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099583

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel